Physician profile
William Edward Gilli
NPI 1447257100
$5,414.10
in general payments reported to CMS, 2019-2025
41 companies · $1,337 in 2025
The $1,337 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,475 · 2020: $179 · 2021: $106 · 2022: $335 · 2023: $809 · 2024: $1,174 · 2025: $1,337.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,319.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,318.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $538.10 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $526.45 | 2019-2025 | |
| Lilly USA, LLC | $322.72 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $321.84 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Amgen INC. | $313.03 | 2019-2025 | Repatha, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $312.30 | 2019-2025 | Jardiance, Synjardy |
| Glaxosmithkline, LLC. | $272.96 | 2022-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Otsuka America Pharmaceutical, INC. | $266.20 | 2022-2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $264.88 | 2019-2025 | Xifaxan |
| Astellas Pharma US INC | $247.09 | 2019-2025 | Veozah, Myrbetriq |
| Teva Pharmaceuticals USA, INC. | $218.90 | 2019-2024 | Uzedy |
| Sanofi-Aventis U.S. LLC | $175.80 | 2019-2023 | |
| Abbott Laboratories | $153.88 | 2019-2025 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $146.15 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $124.47 | 2019-2025 | Capvaxive |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $108.84 | 2019 | |
| Shield Therapeutics INC | $101.98 | 2023-2025 | Accrufer |
| Abbvie INC. | $87.67 | 2023-2025 | |
| Exact Sciences Corporation | $84.74 | 2023-2024 | Cologuard Collection Kit |
| Daiichi Sankyo INC. | $83.75 | 2019-2024 | Injectafer |
| Takeda Pharmaceuticals U.S.A., INC. | $76.37 | 2023-2025 | Trintellix |
| Scilex Pharmaceuticals INC. | $70.00 | 2023 | Ztlido, Elyxyb |
| Nevro Corp. | $62.47 | 2023 | Senza |
| Vertex Pharmaceuticals Incorporated | $59.64 | 2024-2025 | |
| Phathom Pharmaceuticals, INC. | $53.75 | 2024-2025 | Voquezna |
| Dexcom, INC. | $53.19 | 2023-2024 | Dexcom G6 Transmitter |
| Baxter Healthcare | $46.29 | 2024 | Hillrom - Monarch Airway Clearance System |
| Sanofi Pasteur INC. | $44.95 | 2019-2020 | |
| Amarin Pharma, INC. | $35.66 | 2019 | |
| Abiomed | $30.92 | 2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $26.38 | 2022 | |
| Thea Pharma INC. | $23.71 | 2025 | Iyuzeh |
| Idorsia Pharmaceuticals US INC | $23.62 | 2023 | Quviviq |
| Alexion Pharmaceuticals, INC. | $22.37 | 2024 | Ultomiris |
| Supernus Pharmaceuticals, INC. | $22.31 | 2020 | |
| Lundbeck LLC | $19.16 | 2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.45 | 2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $14.80 | 2025 | Fanapt |
| Tolmar, INC. | $13.87 | 2025 | Jatenzo |
| Mylan Specialty L.P. | $13.56 | 2024 | Yupelri |
| Ironwood Pharmaceuticals, INC | $12.88 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Gilli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.